Who Generates More Revenue? Cytokinetics, Incorporated or TG Therapeutics, Inc.

Biotech Revenue Battle: Cytokinetics vs. TG Therapeutics

__timestamp	Cytokinetics, Incorporated	TG Therapeutics, Inc.
Wednesday, January 1, 2014	46940000	152381
Thursday, January 1, 2015	28658000	152381
Friday, January 1, 2016	106407000	152381
Sunday, January 1, 2017	13368000	152381
Monday, January 1, 2018	31501000	152000
Tuesday, January 1, 2019	26868000	152000
Wednesday, January 1, 2020	55828000	152000
Friday, January 1, 2021	70428000	6689000
Saturday, January 1, 2022	94588000	2785000
Sunday, January 1, 2023	7530000	233662000

Unleashing insights

Revenue Race: Cytokinetics vs. TG Therapeutics

In the competitive landscape of biotechnology, revenue generation is a key indicator of success. Over the past decade, Cytokinetics, Incorporated and TG Therapeutics, Inc. have been vying for dominance. From 2014 to 2023, Cytokinetics consistently outperformed TG Therapeutics in revenue, except for a dramatic shift in 2023. Cytokinetics saw a significant revenue drop to approximately $7.5 million, while TG Therapeutics surged to over $233 million, marking a staggering 3,000% increase from its previous year. This shift highlights the volatile nature of the biotech industry, where strategic decisions and market conditions can rapidly alter financial standings. As we look to the future, the question remains: will Cytokinetics reclaim its lead, or will TG Therapeutics continue its upward trajectory?

Published by

U.S. Securities and Exchange Commission

Source link

sec.gov

Date published

17 Jan 2025